Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Approximately 142,000 new cases and 51,000 deaths are predicted for the year 2013. A better understanding of the molecular events leading to cancer progression and chemoresistance is needed in order to improve the overall survival of CRC patients. Our lab has been intensively focused on elucidating the role of a novel family of protein phosphatases, PHLPP (PH domain Leucine-rich-repeats Protein Phosphatase), in inhibiting CRC initiation and progression. We have made substantial progress in understanding the functional importance of PHLPP as a tumor suppressor as well as the molecular mechanism underlying PHLPP regulation. In this proposed study, we will determine the effect of PHLPP-loss on modulating lipid metabolism in CRC. Although recent advances in cancer metabolism research have begun to elucidate how metabolic changes support cancer cell growth and survival, the regulation and functional importance of altered lipid metabolism in CRC remain elusive. This proposal centers on a novel hypothesis that PHLPP-loss plays a pivotal role in driving CRC progression by promoting lipogenesis. In exciting recent findings, we demonstrate that downregulation of PHLPP expression results in an increase in the expression of activated SREBP1, a key activator of lipid biosynthesis. Consistently, MEF cells isolated from PHLPP knockout mice have enhanced lipogenesis during differentiation into adipocytes. In addition, we have found that silencing PHLPP expression leads to increased glucose uptake, lactate production, Krebs cycle activity, and triacylglycerides accumulation in CRC cells, suggesting a role of PHLPP in regulating cellular metabolism. The central hypothesis driving this proposed study is that PHLPP plays an essential role in inhibiting lipogenesis by negatively regulating the PI3K/Akt/mTOR pathway, and loss of PHLPP expression promotes CRC progression as the result of metabolic reprogramming. The following specific aims are proposed: 1) to delineate the molecular mechanism by which PHLPP regulates lipogenesis in CRC cells. We will perform the Stable Isotope-Resolved Metabolomics (SIRM) analysis to determine how PHLPP-loss affects lipid metabolism in CRC cells; 2) to determine the functional importance of PHLPP-mediated regulation of lipogenesis. We will test if PHLPP-loss renders CRC cells more resistant to metabolic stress and chemotherapy drugs as the result of alterations in lipogenesis; and 3) to define the role of PHLPP in suppressing lipogenesis in vivo. The effect of PHLPP-loss on modulating lipid metabolism will be determined using both genetically modified mouse models and patient-derived xenograft models. Results from our studies will fill an important knowledge gap on how altered lipogenesis affects the prognosis and treatment efficacy in CRC patients. Ultimately, by providing insight into the mechanisms by which PHLPP-mediated lipogenesis, our findings will help to develop new treatment strategies in CRC patients.

Public Health Relevance

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Approximately 140,000 new cases and 51,000 deaths are predicted for the year 2013. Although there has been some modest improvement in survival, a better understanding of the molecular events leading to cancer progression and treatment resistance is needed in order to improve the prognosis of CRC patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA133429-11
Application #
9379843
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Yassin, Rihab R
Project Start
2009-04-01
Project End
2019-11-30
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Biochemistry
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40526
Zaytseva, Yekaterina Y; Rychahou, Piotr G; Le, Anh-Thu et al. (2018) Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget 9:24787-24800
Goretsky, Tatiana; Bradford, Emily M; Ye, Qing et al. (2018) Beta-catenin cleavage enhances transcriptional activation. Sci Rep 8:671
Banerjee, Moumita; Cui, Xiaoyu; Li, Zhichuan et al. (2018) Na/K-ATPase Y260 Phosphorylation-mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth. Sci Rep 8:12322
Wen, Yang-An; Xiong, Xiaopeng; Zaytseva, Yekaterina Y et al. (2018) Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis 9:265
Dhar, Sanjit K; Bakthavatchalu, Vasudevan; Dhar, Bithika et al. (2018) DNA polymerase gamma (Pol?) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling. Oncogene 37:6225-6242
Xiong, Xiaopeng; Wen, Yang-An; Mitov, Mihail I et al. (2017) PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells. Cell Death Discov 3:16103
Wen, Yang-An; Xing, Xiaopeng; Harris, Jennifer W et al. (2017) Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis 8:e2593
Liu, Yi; Zhang, Cuiping; Li, Zhenyu et al. (2017) Latexin Inactivation Enhances Survival and Long-Term Engraftment of Hematopoietic Stem Cells and Expands the Entire Hematopoietic System in Mice. Stem Cell Reports 8:991-1004
Jafari, Naser; Zheng, Qiaodan; Li, Liqing et al. (2016) p70S6K1 (S6K1)-mediated Phosphorylation Regulates Phosphatidylinositol 4-Phosphate 5-Kinase Type I ? Degradation and Cell Invasion. J Biol Chem 291:25729-25741
Goretsky, Tatiana; Bradford, Emily M; Ryu, Hyunji et al. (2016) A Cytosolic Multiprotein Complex Containing p85? Is Required for ?-Catenin Activation in Colitis and Colitis-associated Cancer. J Biol Chem 291:4166-77

Showing the most recent 10 out of 30 publications